Corium International Inc (NASDAQ:CORI) – Equities researchers at Cantor Fitzgerald decreased their FY2018 EPS estimates for Corium International in a research report issued to clients and investors on Tuesday. Cantor Fitzgerald analyst W. Tanner now expects that the biopharmaceutical company will earn ($1.33) per share for the year, down from their previous estimate of ($1.32). Cantor Fitzgerald has a “Buy” rating and a $14.00 price target on the stock.

Corium International (NASDAQ:CORI) last announced its quarterly earnings results on Thursday, November 16th. The biopharmaceutical company reported ($0.36) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.43) by $0.07. Corium International had a negative return on equity of 482.64% and a negative net margin of 149.99%.

Several other brokerages also recently issued reports on CORI. Zacks Investment Research upgraded Corium International from a “sell” rating to a “hold” rating in a research report on Tuesday, November 28th. Needham & Company LLC lifted their price objective on Corium International from $13.00 to $16.00 and gave the stock a “buy” rating in a research report on Monday, November 20th. HC Wainwright assumed coverage on Corium International in a research report on Tuesday, September 26th. They set a “buy” rating and a $15.00 price objective for the company. ValuEngine upgraded Corium International from a “sell” rating to a “hold” rating in a research report on Sunday, December 31st. Finally, Jefferies Group set a $10.00 price objective on Corium International and gave the stock a “buy” rating in a research report on Sunday, October 29th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and six have assigned a buy rating to the company’s stock. Corium International currently has a consensus rating of “Buy” and an average price target of $12.86.

Shares of Corium International (NASDAQ:CORI) traded up $0.26 during trading on Thursday, hitting $12.31. The company had a trading volume of 294,300 shares, compared to its average volume of 190,236. The company has a debt-to-equity ratio of 2.41, a current ratio of 2.70 and a quick ratio of 2.60. Corium International has a 1 year low of $2.67 and a 1 year high of $12.33. The firm has a market cap of $452.50, a P/E ratio of -7.37 and a beta of 1.26.

In other Corium International news, major shareholder Healthcare Master Fun Broadfin sold 500,000 shares of the business’s stock in a transaction on Friday, November 17th. The stock was sold at an average price of $10.96, for a total value of $5,480,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 46.50% of the company’s stock.

A number of institutional investors and hedge funds have recently modified their holdings of the business. Schwab Charles Investment Management Inc. raised its holdings in Corium International by 47.3% in the 4th quarter. Schwab Charles Investment Management Inc. now owns 49,509 shares of the biopharmaceutical company’s stock valued at $476,000 after acquiring an additional 15,909 shares during the last quarter. New York State Common Retirement Fund acquired a new position in Corium International in the 2nd quarter valued at $158,000. Bank of New York Mellon Corp raised its holdings in Corium International by 33.7% in the 3rd quarter. Bank of New York Mellon Corp now owns 88,445 shares of the biopharmaceutical company’s stock valued at $980,000 after acquiring an additional 22,285 shares during the last quarter. California State Teachers Retirement System acquired a new position in Corium International in the 2nd quarter valued at $263,000. Finally, Teachers Advisors LLC acquired a new position in Corium International in the 2nd quarter valued at $272,000. Institutional investors own 89.08% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “FY2018 EPS Estimates for Corium International Inc (CORI) Cut by Cantor Fitzgerald” was reported by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another website, it was stolen and reposted in violation of U.S. & international copyright legislation. The legal version of this story can be viewed at https://www.watchlistnews.com/fy2018-eps-estimates-for-corium-international-inc-cori-cut-by-cantor-fitzgerald/1812540.html.

Corium International Company Profile

Corium International, Inc is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products. As of September 30, 2016, the Company had multiple programs in preclinical and clinical development focused primarily on the treatment of neurological disorders, with two lead programs in Alzheimer’s disease.

Earnings History and Estimates for Corium International (NASDAQ:CORI)

Receive News & Ratings for Corium International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corium International and related companies with MarketBeat.com's FREE daily email newsletter.